Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action

Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action

Aromatase inhibitors (AIs) reduce breast cancer recurrence and prolong survival, but up to 30% of patients exhibit recurrence. Using a genome-wide association study of patients entered on MA.27, a phase III randomized trial of anastrozole versus exemestane, we identified a single nucleotide polymorp...

Full description

Bibliographic Details
Main Authors: Junmei Cairns, James N. Ingle, Tanda M. Dudenkov, Krishna R. Kalari, Erin E. Carlson, Jie Na, Aman U. Buzdar, Mark E. Robson, Matthew J. Ellis, Paul E. Goss, Lois E. Shepherd, Barbara Goodnature, Matthew P. Goetz, Richard M. Weinshilboum, Hu Li, Mehrab Ghanat Bari, Liewei Wang
Format: Article
Language:English
Published: American Society for Clinical investigation 2020-08-01
Series:JCI Insight
Subjects:
Oncology
Therapeutics
Online Access:https://doi.org/10.1172/jci.insight.137571

Internet

https://doi.org/10.1172/jci.insight.137571

Similar Items